PI 3-Kinase p-110-beta regulation of platelet integrin alpha-II-beta-3

Shaun Jackson, Simone Schoenwaelder

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

Abstract

From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here
Original languageEnglish
Title of host publicationPhosphoinositide 3-kinase in Health and Disease
EditorsChristian Rommel, Bart Vanhaesebroeck, Peter K Vogt
Place of PublicationUS
PublisherSpringer
Pages203 - 224
Number of pages22
Edition1st
ISBN (Print)9783642136627
Publication statusPublished - 2010

Cite this